Head to Head Comparison: Prime Medicine (NYSE:PRME) versus Finch Therapeutics Group (NASDAQ:FNCH)

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) and Prime Medicine (NYSE:PRME – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Analyst Recommendations

This is a summary of current recommendations for Finch Therapeutics Group and Prime Medicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	2	0	3.00
Prime Medicine	0	0	0	0	N/A

Finch Therapeutics Group presently has a consensus price target of $17.00, indicating a potential upside of 4,440.60%. Given Finch Therapeutics Group’s higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than Prime Medicine.

Institutional and Insider Ownership

21.0% of Finch Therapeutics Group shares are held by institutional investors. 44.6% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Finch Therapeutics Group and Prime Medicine’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	$1.66 million	10.81	-$58.16 million	($2.25)	-0.17
Prime Medicine	$5.21 million	252.55	-$121.82 million	N/A	N/A

Finch Therapeutics Group has higher earnings, but lower revenue than Prime Medicine.

Profitability

This table compares Finch Therapeutics Group and Prime Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	-6,431.16%	-52.79%	-41.29%
Prime Medicine	N/A	N/A	N/A

About Finch Therapeutics Group

(Get Rating)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

About Prime Medicine

(Get Rating)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.